Abstract
Data on availability and cost of anti-tuberculosis (TB) drugs in relation to affordability at national level are scarce.
我们在availabili进行了横断面研究ty and cost of anti-TB drugs at major TB-reference centres in 37 European countries. Costs of standardised treatment regimens used for pan-sensitive TB, multidrug-resistant (MDR) TB, pre-extensively drug-resistant (XDR) TB, and XDR-TB were compared using a purchasing power analysis. Affordability was evaluated in relation to monthly national gross domestic products per capita (GDP).
At least one second-line injectable and either moxifloxacin or levofloxacin were available in all countries. Linezolid and clofazimine were available in 79% and 46% of the countries, respectively. Drug cost for XDR-TB was three-times more expensive than those for MDR-TB. The average price of treatment for pan-sensitive TB represented a maximum of 8.5% of the monthly GDP across countries, while for standard MDR-TB treatment this was <30% in only six countries and more than 100% in four countries. Treatment of XDR-TB represented more than 100% of a month's GDP in all countries where the regimen was available.
High cost and limited availability of drugs for treatment of drug-resistant TB, particularly beyond resistance to first-line drugs, are a major impediment to successful TB control in Europe.
Abstract
Limited availability and high cost of drugs hamper the treatment of drug-resistant tuberculosis in Europehttp://ow.ly/CrhbM
Footnotes
Earn CME accreditation by answering questions about this article. You will find these atwww.qdcxjkg.com/misc/cmeinfo.xhtml
Support statement: This work was supported by the European Commission's Seventh Framework Programme (FP7/2007-2013) under grant agreement FP7-223681, and the German Center for Infection Research, DZIF. The funders had no role in the design, implementation or analysis of the study, nor in the preparation or decision to publish the manuscript.
Conflict of interest: Disclosures can be found alongside the online version of this article atwww.qdcxjkg.com
- ReceivedJuly 8, 2014.
- AcceptedSeptember 29, 2014.
- Copyright ©ERS 2015